An injection of venture capital will help transform switch specialist Maxwellia into a pioneering “research and development (R&D) engine” for the European OTC industry, according to the firm’s chief executive officer Anna Maxwell.
Speaking to OTC bulletin, Maxwell claimed the £0.7 million (€0.8 million) ‘early- stage’ funding was a “game-changer” for the UK-based...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?